Unusually Large $75.00K Block in Put Contracts on May 4th, 2023 at 09:30:05 ET RailMada Therapeutics (RLMD) was sold, with a strike price of $3.00 / share, expiring 134 days (on September 15, 2023).
This trade was first picked up on Fintel Realtime option flow Tools, where unusual option trades are highlighted.
What is Fund Sentiment?
there are 251 Reporting of fund or institution positions Relmada in Medical Sciences. This is a decrease of 30 owners or 10.68% from the previous quarter. average portfolio weight of all funds 0.05% dedicated to RLMD, a reduction of 82.22%. The total shares owned by the institutions decreased by 22.35% to 20,207K shares in the last three months. put/call ratio RLMD of 0.40 indicates a bullish outlook.
Analyst Price Forecast Indicates 326.56% Upside
By April 24, 2023, average one year price target Relmada is 11.60 for medical science. Forecasts range from a low of $3.03 to a high of $27.30. The average price target shows an upside of 326.56% from its latest informed closing price of 2.72.
see our Leaderboard of companies With the biggest price target on the upside.
The estimated annual revenue for Relmada Therapeutics is 0MM. Estimated Annual Non-GAAP eps is -3.40.
What are the other shareholders doing?
Deep Track Capital The company holds 2,838K shares representing 9.43% ownership. In its prior filing, the firm reported representing 461K shares. a hike of 83.76%. Firm fell short of Its portfolio allocation in RLMD has increased by 46.78% as compared to the previous quarter.
rtw investment The company holds 2,068K shares representing 6.87% ownership. In its prior filing, the firm reported representing 2,644K shares. fall short of 27.89%. Firm fell short of Its portfolio allocation in RLMD has increased by 93.47% over the previous quarter.
Acadian Asset Management The company holds 1,100K shares representing 3.66% ownership.
Millennium Management The company holds 1,062K shares representing 3.53% ownership. In its prior filing, the firm reported owning 20K shares, representing a hike of 98.14%. Firm increased Its portfolio allocation in RLMD has increased by 374.97% as compared to the previous quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares The company holds 905K shares representing 3.01% ownership. No change from last quarter.
Relmada Medical Science Background Information
(This description is provided by the company.)
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Its experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada’s flagship program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.
View All Railmada Therapeutics regulatory filing,
This story originally appeared on fintail,
The views and opinions expressed here are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.